Pharmacology and mechanisms of action of new oral anticoagulants, Fundam Clin Pharmacol, vol.29, pp.10-20, 2015. ,
Xarelto® (rivaroxaban) Summary of Product characteristics, Pharma AG), 2019. ,
The balance of pro-and anticoagulant processes underlying thrombin generation, J Thromb Haemost, vol.13, pp.437-484, 2015. ,
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants, Thromb Haemost, vol.118, pp.437-50, 2018. ,
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor, Clin Pharmacol Ther, vol.78, pp.412-433, 2005. ,
Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement, Thromb Haemost, vol.100, pp.453-61, 2008. ,
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery, Clin Pharmacokinet, vol.47, pp.203-219, 2008. ,
The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor, J Clin Pharmacol, vol.53, pp.249-55, 2013. ,
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring, Thromb J, vol.11, p.10, 2013. ,
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban, Can J Cardiol, vol.29, pp.24-33, 2013. ,
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban, Clin Pharmacokinet, vol.53, pp.1-16, 2014. ,
Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?, Blood Coagul Fibrinolysis, vol.26, pp.925-958, 2015. ,
Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin, J Thromb Haemost JTH, vol.15, pp.273-83, 2017. ,
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants, J Thromb Haemost JTH, vol.16, pp.842-850, 2018. ,
Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity, J Clin Pharmacol, vol.47, pp.1398-407, 2007. ,
Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial, Thromb Haemost, vol.114, pp.258-67, 2015. ,
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity, N Engl J Med, vol.373, pp.2413-2437, 2015. ,
Comparative assessment of the anticoagulant activity of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation: a noninterventional study, Medicine (Baltimore), vol.95, p.3037, 2016. ,
Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay, Res Pract Thromb Haemost, vol.1, pp.194-201, 2017. ,
Dissociation between the pharmacokinetics and pharmacodynamics of oncedaily rivaroxaban and twice-daily apixaban: a randomized crossover study, J Thromb Haemost, vol.15, pp.2017-2045, 2017. ,
Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement, J Thromb Thrombolysis, vol.43, pp.562-571, 2017. ,
Effect of rivaroxaban on thrombin generation in vivo. A study in obese patients, Int J Lab Hematol, vol.40, pp.11-15, 2018. ,
Are screening tests reliable to rule out direct oral anticoagulant plasma levels at various thresholds (30, 50, or 100 ng/ml) in emergency situations?, Chest, vol.153, pp.288-290, 2018. ,
Global assays and the management of oral anticoagulation, Thromb J, vol.13, p.9, 2015. ,
Detection of direct oral factor Xa inhibitors anticoagulants by modified rotational thromboelastometry, Eur. J. Anaesth, vol.36, pp.449-456, 2019. ,
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban, J Thromb Haemost, vol.5, pp.886-894, 2007. ,
In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux, Thromb Res, vol.129, pp.77-82, 2012. ,
Al Dieri R. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation, Haematologica, vol.98, pp.549-54, 2013. ,
Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay, Am J Clin Pathol, vol.143, pp.241-248, 2015. ,
Comment on the use of computational models to study the effect of apixaban and rivaroxaban on thrombin generation, Thromb Haemost, vol.115, pp.869-70, 2016. ,
How the direct oral anticoagulant apixaban affects thrombin generation parameters, Thromb Res, vol.135, pp.1186-90, 2015. ,
A review of commercially available thrombin generation assays, Res Pract Thromb Haemost, vol.2, pp.42-50, 2018. ,
Calibrated automated thrombin generation measurement in clotting plasma, Pathophysiol Haemost Thromb, vol.33, pp.4-15, 2003. ,
Thrombin generation analysis with a new automated system (ST-Genesia): interseries performances during DRIVING study and comparison with CAT system. 64 th Annual Scientific and Standardization Committee meeting -ISTH, 2018. ,
Comparison between the standard thrombin generation method and the automated hrombin generation ,
Team nlme: Linear and Nonlinear Mixed Effects Models, 2018. ,
R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2018. ,
Large external quality assessment suvery on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma, Thromb Res, vol.136, pp.125-155, 2015. ,
In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban, J Thromb Haemost, vol.11, pp.1111-1119, 2013. ,
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo, J Thromb Haemost, vol.12, pp.1054-65, 2014. ,
Comment on the use of computational models to study the effect of apixaban and rivaroxaban on thrombin generation, Thromb Haemost, vol.115, pp.869-70, 2016. ,
Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model, Fundam Clin Pharmacol, vol.31, issue.3, pp.347-58, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01623733
Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing, Br J Haematol, vol.147, pp.77-82, 2009. ,
Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the ,
, American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain, Reg Anesth Pain Med, vol.40, pp.182-212, 2015.
Susen S; French Working Group on Perioperative Hemostasis (GIHP). Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP, Anaesth Crit Care Pain Med, vol.36, pp.73-76, 2015. ,
Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing, PloS One, vol.12, p.176967, 2017. ,
Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT), Thromb Haemost, vol.95, pp.772-777, 2006. ,
Age-dependency of thrombin generation, Thromb Haemost, vol.95, pp.756-763, 2006. ,
Mechanism-Based Pharmacodynamic Modeling, Computational Toxicology: Volume I, pp.583-600, 2012. ,
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial, Lancet, vol.385, pp.2288-95, 2015. ,